Get the Stockscreener App
1.18
0.84%
-0.01
Allarity Therapeutics Inc stock is traded at $1.18, with a volume of 199.09K.
It is down -0.84% in the last 24 hours and down -22.37% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
See More
Previous Close:
$1.19
Open:
$1.12
24h Volume:
199.09K
Relative Volume:
0.03
Market Cap:
$17.25M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00573
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
+2.61%
1M Performance:
-22.37%
6M Performance:
+21.65%
1Y Performance:
-16.31%
1-Day Range:
$1.09
$1.22
1-Week Range:
$1.09
$1.32
52-Week Range:
$0.6138
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.18 | 17.28M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Stock (ALLR) Latest News
How Allarity Therapeutics Inc. stock reacts to oil pricesJuly 2025 Selloffs & Smart Swing Trading Techniques - newser.com
Why retail investors pile into Allarity Therapeutics Inc. stockSwing Trade & Daily Price Action Insights - newser.com
Will Allarity Therapeutics Inc. stock continue upward momentumPortfolio Value Report & Stepwise Trade Execution Plans - newser.com
Published on: 2025-11-16 01:34:25 - newser.com
Can momentum traders help lift Allarity Therapeutics Inc.Quarterly Trade Review & Short-Term High Return Strategies - newser.com
Published on: 2025-11-15 17:56:44 - newser.com
Exit strategy if you’re trapped in Allarity Therapeutics Inc.Quarterly Profit Summary & Expert Verified Movement Alerts - newser.com
Real time breakdown of Allarity Therapeutics Inc. stock performance2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Why hedge funds are buying Allarity Therapeutics Inc. stockTrade Performance Summary & Consistent Income Trade Ideas - newser.com
Published on: 2025-11-14 20:27:35 - newser.com
Real time pattern detection on Allarity Therapeutics Inc. stockWeekly Investment Report & Verified Momentum Watchlists - newser.com
Why Allarity Therapeutics Inc. stock appeals to analystsProduct Launch & Fast Exit/Entry Strategy Plans - newser.com
Key facts: Allarity Therapeutics reports $7.9M Q3 loss; R&D expenses rise - TradingView
Using AI based signals to follow Allarity Therapeutics Inc.2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - newser.com
What earnings revisions data tells us about Allarity Therapeutics Inc.Index Update & Risk Controlled Swing Trade Alerts - newser.com
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - Investing News Network
Allarity Therapeutics's Q3 net loss narrows - MarketScreener
Allarity Therapeutics, Inc. SEC 10-Q Report - TradingView
Applying big data sentiment scoring on Allarity Therapeutics Inc.Fed Meeting & Fast Gain Stock Trading Tips - newser.com
What drives Allarity Therapeutics Inc stock priceFundamental Stock Analysis & Secret Picks Wall Street Isn’t Talking About - earlytimes.in
Using economic indicators to assess Allarity Therapeutics Inc. potentialJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Published on: 2025-11-11 02:28:50 - newser.com
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):